SBIR/STTR Research Award

Modification of Intervertebral Disk Fatigue Resistance

Award identifier 3a3f89ae49bc38bc80ef8bb7df5ac1649b97ccbac116530a02f2051a77cb01e7Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$98,894

Program and phase

STTR · Phase I

Award year

2001

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Ampac Biotechnology, Inc.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (Provided by Applicant): An investigation is proposed exploring the use of biochemical reagents to improve fatigue resistance of intervertebral disc tissue. While not well quantified, the capacity of spinal tissue to withstand repetitive loading is a critically important factor in the progression of spinal osteoarthritis. Current treatments for spinal instability and low-back pain, including spinal fusion, are generally ineffective in slowing the progression of degeneration. Biochemical alterations in the structure of the annular matrix could have significant effects on the disc's ability to withstand repetitive mechanical loading. We intend to study the effectiveness of certain reagents in maintaining the mechanical properties of disc tissues subjected to non-traumatic fatigue loading. Preliminary experiments in our laboratory using novel destructive and non-destructive mechanical testing techniques have shown degradation of elastic-plastic and viscoelastic material properties of disc tissues subjected to non-traumatic cyclic loads. If these reagents are effective in improving fatigue resistance of intervertebral discs, a new, minimally invasive treatment may be developed which will be able to improve the degenerated disc's ability to withstand repetitive physiological loads. This type of treatment has the potential of improving or even replacing numerous surgical interventions directed at the ubiquitous problems of low back pain and instability. PROPOSED COMMERCIAL APPLICATION: Back pain and disability associated with spinal degeneration and instability is without question one of the costliest health problems in western civilization (in the range of $20 billion U.S. annually- low-back-pain alone). The commercial potential of a minimally invasive treatment (perhaps a series of injections) capable of arresting degradation and stabilizing intervertebral discs would be staggering. In addition, such treatment could be used as an additional preventative procedure in fusion surgery, where accelerated degeneration commonly occurs at the level adjacent to the fusion.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.